

Choudhury, A.I., Heffron, H., Smith, M.A., Al-Qassab, H., Xu, A.W., Selman, C., Simmgen, M., Clements, M., Claret, M., MacColl, G., Bedford, D.C., Hisadome, K., Diakonov, I., Moosajee, V., Bell, J.D., Speakman, J.R., Batterham, R.L., Barsh, G.S., Ashford, M.L.J., and Withers, D.J. (2005) The role of insulin receptor substrate 2 in hypothalamic and β cell function. *Journal of Clinical Investigation*, 115 (4). pp. 940-950. ISSN 0021-9738

Copyright © 2005 American Society for Clinical Investigation

A copy can be downloaded for personal non-commercial research or study, without prior permission or charge

The content must not be changed in any way or reproduced in any format or medium without the formal permission of the copyright holder(s)

When referring to this work, full bibliographic details must be given

<http://eprints.gla.ac.uk/78699/>

Deposited on: 26 April 2013

Research Article

The role of insulin receptor substrate 2 in hypothalamic and β cell function

Agharul I. Choudhury¹, Helen Heffron¹, Mark A. Smith², Hind Al-Qassab¹, Allison W. Xu³, Colin Selman¹, Marcus Simmgen¹, Melanie Clements¹, Marc Claret¹, Gavin MacColl¹, David C. Bedford¹, Kazunari Hisadome², Ivan Diakonov¹, Vazira Moosajee⁴, Jimmy D. Bell⁴, John R. Speakman⁵, Rachel L. Batterham¹, Gregory S. Barsh³, Michael L.J. Ashford² and Dominic J. Withers¹

¹Centre for Diabetes and Endocrinology, Rayne Institute, University College London, London, United Kingdom.

²Neurosciences Institute, Division of Pathology and Neuroscience, Ninewells Hospital and Medical School, University of Dundee, Dundee, United Kingdom.

³Departments of Genetics and Pediatrics, Stanford University School of Medicine, Stanford, California, USA.

⁴Molecular Imaging Group, Medical Research Council Clinical Sciences Centre, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, London, United Kingdom.

⁵Aberdeen Centre for Energy Regulation and Obesity (ACERO), School of Biological Sciences, University of Aberdeen, Aberdeen, United Kingdom.

Address correspondence to: Dominic Withers, Centre for Diabetes and Endocrinology, Rayne Institute, University College London, 5 University Street, London WC1E 6JJ, United Kingdom. Phone: 44-20-7679-6586; Fax: 44-20-7679-6211; E-mail: d.withers@ucl.ac.uk.

First published March 1, 2005

Received for publication January 10, 2005, and accepted in revised form February 22, 2005.

Insulin receptor substrate 2 (*Irs2*) plays complex roles in energy homeostasis. We generated mice lacking *Irs2* in β cells and a population of hypothalamic neurons (*RIPCreIrs2KO*), in all neurons (*NesCreIrs2KO*), and in proopiomelanocortin neurons (*POMCCreIrs2KO*) to determine the role of *Irs2* in the CNS and β cell. *RIPCreIrs2KO* mice displayed impaired glucose tolerance and reduced β cell mass. Overt diabetes did not ensue, because β cells escaping Cre-mediated recombination progressively populated islets. *RIPCreIrs2KO* and *NesCreIrs2KO* mice displayed hyperphagia, obesity, and increased body length, which suggests altered melanocortin action. *POMCCreIrs2KO* mice did not display this phenotype. *RIPCreIrs2KO* and *NesCreIrs2KO* mice retained leptin sensitivity, which suggests that CNS *Irs2* pathways are not required for leptin action. *NesCreIrs2KO* and *POMCCreIrs2KO* mice did not display reduced β cell mass, but *NesCreIrs2KO* mice displayed mild abnormalities of glucose homeostasis. *RIPCre* neurons did not express POMC or neuropeptide Y. Insulin and a melanocortin agonist depolarized *RIPCre*

neurons, whereas leptin was ineffective. Insulin hyperpolarized and leptin depolarized POMC neurons. Our findings demonstrate a critical role for IRS2 in β cell and hypothalamic function and provide insights into the role of RIPCre neurons, a distinct hypothalamic neuronal population, in growth and energy homeostasis.

Introduction

Insulin regulates peripheral energy homeostasis by acting on multiple tissues to control carbohydrate, lipid, and protein metabolism (1). Gene targeting in mice has shown that β cell deletion of the insulin receptor causes reduced first-phase insulin release, reduced β cell insulin content, and progressive deterioration in glucose tolerance (2). Early studies of the effects of insulin in the CNS demonstrated a role for intracerebroventricularly administered insulin in the control of food intake and body weight (3). Mouse brain insulin receptor deletion causes mild hyperphagia and adiposity in female mice, diet-sensitive obesity, and defects in reproductive function (4). Results from studies in which insulinomimetics and insulin receptor antisense were centrally administered also support a role for CNS insulin signaling in energy homeostasis regulation (5, 6). Insulin signaling mechanisms therefore regulate β cell and CNS function, but it is unclear which postreceptor components mediate which physiological effects and, in the case of the CNS, which neuronal populations are involved. It is also unclear how insulin signaling components interact with other molecules involved in energy homeostasis, such as leptin.

Insulin receptor substrate (Irs) proteins lie downstream of the activated insulin and type 1 insulin-like growth factor receptor (7). Gene targeting studies have revealed distinct physiological roles for the 4 major Irs proteins (7). Mice lacking *Irs1* display profound growth retardation and insulin resistance but, due to β cell compensation, do not develop diabetes (8, 9). *Irs3*- and *Irs4*-null mice have minimal metabolic, endocrine, and growth phenotypes (7). In contrast, mice lacking *Irs2* develop diabetes due to insulin resistance and pancreatic β cell dysfunction (10). These studies have suggested that *Irs2* is the major mediator of the metabolic effects of insulin and have identified a novel role for *Irs2* signaling in the maintenance of β cell mass. *Irs2* signaling also plays complex roles in neuroendocrine function. Female *Irs2*-null mice are infertile, hyperphagic, and develop obesity (11). *Irs2*-null mice are reported to be leptin resistant (12), which suggests that *Irs2* acts as a point of convergence for leptin and insulin signaling.

It has recently been reported that mice lacking *Irs2* in both pancreatic β cells and a poorly defined hypothalamic neuronal population (generated using a rat insulin 2 promoter Cre [RIPCre] recombinase transgene) display reduced islet mass, impaired glucose tolerance, and hypothalamic dysfunction (13, 14). Unlike mice with global deletion of *Irs2*, these mice did not develop progressive diabetes. One study (13) reported that they displayed a hypothalamic phenotype suggesting melanocortin dysfunction, proposed that RIPCre neurons are proopiomelanocortin (POMC) neurons, and noted β cell recovery with time through an undetermined mechanism. Another study (14) demonstrated reduced islet mass, obesity, and leptin resistance but did not report other features of hypothalamic dysfunction or long-term analysis of islet function. Consequently, these studies have raised a number of critical but unanswered questions (15). In particular it is unclear (a) why there is a relative recovery of the β cell phenotype; (b) what role the CNS plays in the β cell phenotype and the impairment of glucose homeostasis; (c) what is the role of *Irs2* in leptin action; and (d) what are the identity and characteristics of the hypothalamic neuronal population involved (15).

To address these questions, we generated mice lacking *Irs2* in specific cell types: *RIPCreIrs2KO* mice, lacking *Irs2* in β cells and a poorly characterized population of hypothalamic neurons; *NesCreIrs2KO* mice, lacking *Irs2* in all neurons but not the endocrine pancreas; and *POMCCreIrs2KO* mice, lacking *Irs2* in POMCCre-expressing cells.

Results

Generation of mice with a floxed allele of *Irs2*. We generated mice with a floxed allele of *Irs2* (*Irs2lox* mice) to permit its deletion in different cell types and tissues (Figure 1, A–E). *Irs2lox* mice, when bred to homozygosity, were phenotypically indistinguishable from wild-type animals and displayed normal *Irs2* expression (data not shown).




Figure 1

Generation of *Irs2lox* mice and characteristics of RIPCre and POMCCre mice. (A) Schema of

targeting construct design, simplified restriction map of the *Irs2* locus, the locus after homologous recombination and the deletion of neomycin cassette (Neo), and Southern blotting and PCR genotyping strategies used to identify these events. External probe A was used to identify homologous recombination (HR), probe B to detect the selection cassette, and probe C to detect the coding region of *Irs2*. HSV-tk, herpes simplex virus thymidine kinase. **(B)** Southern blot analysis with probe A demonstrating homologous recombination after targeting. **(C and D)** Southern blots using probe B after Cre-mediated recombination demonstrating deletion (Del) of the neomycin cassette and using probe C to demonstrate retention of *Irs2* coding region confirming type 2 recombination. **(E)** PCR analysis with primers P1 and P2 of HR clone that has lost the neomycin cassette but retained the loxP site downstream of the *Irs2* coding region. **(F–H)** We examined Cre expression in RIPCre mice by analyzing GFP expression in pancreatic sections costained with insulin and hypothalamic sections from RIPCreZEG mice. **(I)** We examined Cre expression in POMCCre mice by analyzing hypothalamic sections from POMCCreZEG mice. **(J)** Combined ISH for POMC and ICC for GFP was performed in POMCCreZEG mice to confirm Cre expression in POMC neurons. **(K)** Immunohistochemistry for IRS2 (red) was performed in hypothalamic sections from POMCCreZEG mice. Scale bars: 50 μ m **(H, I, and K)** and 10 μ m **(J)**. 3V, third ventricle; ME, median eminence.

Using 3 Cre recombinase transgenic lines, we generated *RIPCreIrs2KO*, *NesCreIrs2KO*, and *POMCCreIrs2KO* mice. We also intercrossed *RIPCre* and *POMCCre* mice with *ZEG* (16) and *Rosa26lacZ* (17) indicator mice on both wild-type and *Irs2lox/lox* backgrounds. This allowed identification of cell types in which recombination occurred and permitted *Irs2* deletion and GFP or lacZ expression in the same cell types. *RIPCreZEG* mice expressed GFP in pancreatic islets, hypothalamic structures such as the arcuate, lateral, and ventromedial hypothalamus (VMH), and a discrete population of forebrain neurons (Figure 1, F–H, and data not shown). In *POMCCreZEG* mice, GFP expression was found in a discrete population of arcuate nucleus neurons (Figure 1I). Combined in situ hybridization (ISH) and immunocytochemistry (ICC) studies demonstrated colocalization of GFP and POMC (Figure 1J) in more than 90% of cells examined, which indicated that most POMC neurons also expressed functional Cre recombinase. No GFP expression was found in pancreatic β cells (data not shown). *NesCre* mice delete in neurons but not pancreatic endocrine cells (18) and have been used to manipulate insulin signaling in the CNS (4). *Irs2* expression was found in pancreatic islets and in the arcuate, the VMH, and the paraventricular nucleus (Figure 1K and Figure 2B and data not shown).




Figure 2

Analysis of deletion of *Irs2* in islets and hypothalamus from *RIPCreIrs2KO*, *POMCCreIrs2KO*, and *NesCreIrs2KO* mice. **(A)** We performed PCR analysis to detect recombination of the *Irs2* locus in DNA from islets and hypothalamus (hypo) of control and knockout mice. The presence of a 1.3-kb PCR product indicates recombination and deletion of the *Irs2* gene. **(B and C)** Western blot analysis of *Irs2* in islets from control and *RIPCreIrs2KO* mice **(B)** and whole brain and hypothalamic lysates from control and *NesCreIrs2KO* mice **(C)**. **(D)** Immunofluorescence analysis for *Irs2* expression in the hypothalamus of *RIPCreZEG* and *RIPCreIrs2KOZEG* mice. Colocalization of GFP (green) and *Irs2* (red) is seen in *RIPCreZEG* mice (indicated by white arrows) and no colocalization in *RIPCreIrs2KOZEG* mice. **(E)** Colocalization of *POMCCre* expression and *Irs2* in *POMCCreZEG* mice. **(F)** Colocalization of *POMCCre* expression and *Irs2* in *POMCCrelacZ* mice and no colocalization of GFP and *Irs2* in *POMCCreIrs2KOlacZ* mice. Confocal images of representative arcuate nucleus fields are shown in **D–F**. Scale bars: 10 μ m.

To confirm deletion of *Irs2* in the *RIPCreIrs2KO*, *NesCreIrs2KO*, and *POMCCreIrs2KO* mice, we analyzed recombination of the *Irs2lox* allele by PCR in islet and hypothalamic DNA. In 4-week-old mice, the recombined allele was detected in both tissues in *RIPCreIrs2KO* mice (Figure 2A) but only in the hypothalamus of *NesCreIrs2KO* and *POMCCreIrs2KO* mice (Figure 2A). Immunoprecipitation and Western blotting confirmed the lack of *Irs2* expression in isolated islets from *RIPCreIrs2KO* and in either whole brain or hypothalamic lysates from *NesCreIrs2KO* mice (Figure 2, B and C). ICC analysis of *RIPCreZEG* mice demonstrated *Irs2* colocalization with GFP in some but not all hypothalamic arcuate neurons (Figure 2D, left panel). In *RIPCreIrs2KOZEG* mice, there was no colocalization of *Irs2* and GFP, which confirmed *Irs2* deletion in *RIPCre* neurons (Figure 2D, right). *Irs2* expression remained in other hypothalamic neurons. Analysis of *Irs2* expression in *POMCCreZEG* mice demonstrated colocalization of *Irs2* with GFP in some POMC neurons (Figure 2E). *Irs2* deletion was confirmed in *POMCCreIrs2KOlacZ* mice (we were unable to breed *POMCCreIrs2KOZEG* mice), but *Irs2* expression remained in other hypothalamic arcuate neurons (Figure 2F). Normal *Irs2* expression was detected in muscle, liver, adipose, and other tissues in mice of all 3 lines (data not shown).

Glucose homeostasis in *RIPCreIrs2KO*, *NesCreIrs2KO*, and *POMCCreIrs2KO* mice. In 4-week-old male *RIPCreIrs2KO*, *NesCreIrs2KO*, and *POMCCreIrs2KO* mice, fasting blood glucose levels were indistinguishable from those of control animals (data not shown). At 12 weeks of age, when male *Irs2*-null mice are diabetic, *RIPCreIrs2KO* mice had higher fasting blood glucose levels than control mice, and glucose tolerance tests revealed defective glucose disposal (Figure 3, A and B). However, the elevation in fasting blood glucose levels was modest, and thus *RIPCreIrs2KO* mice did not display the overt diabetes and catabolic state that *Irs2*-null mice develop. Fasting glucose levels were also elevated in *NesCreIrs2KO* mice, and glucose tolerance was mildly impaired (Figure 3, A and C). *RIPCreIrs2KO* and *NesCreIrs2KO* mice at 6 months of age and older did not develop markedly elevated fasting blood glucose levels but remained glucose intolerant (Figure 3D and data not shown). In contrast, fasting glucose levels and glucose tolerance were equivalent to those of controls in *POMCCreIrs2KO* mice at 12 weeks and older (Figure 3A and data not shown).




Figure 3

Glucose homeostasis in *RIPCreIrs2KO*, *NesCreIrs2KO*, and *POMCCreIrs2KO* mice. **(A)** Fasting blood glucose levels of 12-week-old male mice of the indicated genotypes were measured after a 16-hour overnight fast. **(B)** Glucose tolerance tests were performed on 12-week-old male *RIPCreIrs2KO* (filled squares) and control mice (open squares). **(C)** Glucose tolerance tests were performed on 12-week-old male *NesCreIrs2KO* (filled squares) and control mice (open squares). **(D)** Fasting blood glucose levels of 6-month-old male mice of the indicated genotypes were measured after a 16-hour overnight fast. **(E)** Fasting blood insulin levels of 12-week-old male mice of the indicated genotypes were measured after a 16-hour overnight fast. Data in **A–E** represent the mean \pm SEM for 8–10 animals of each genotype. **(F)** We calculated the percentage of the total pancreatic area occupied by β cells in 12-week-old male mice of the indicated genotypes using insulin-stained pancreatic sections. The right side shows data for 9-month-old *RIPCreIrs2KO* and control mice. Four pancreata were analyzed per genotype at each time point, and for each pancreas, 4 sections were analyzed. The data presented are mean \pm SEM for 4 mice of each genotype. * $P < 0.05$, ** $P < 0.01$, and *** $P < 0.001$. Cont, control.

At 12 weeks, *RIPCreIrs2KO* and *NesCreIrs2KO* mice, but not *POMCCreIrs2KO* mice, displayed fasting hyperinsulinemia compared with control animals, which suggests development of insulin resistance (Figure 3E). At 6 months, both *RIPCreIrs2KO* and *NesCreIrs2KO* mice remained hyperinsulinemic (data not shown). At 4 weeks, when there was a 50% reduction in β cell mass in *Irs2*-null mice (10), no decrease in β cell mass was seen in *RIPCreIrs2KO* compared with control animals (data not shown). However, by 12 weeks, *RIPCreIrs2KO* mice had a 40% reduction in β cell mass compared with control mice (Figure 3F, left), consistent with the deterioration in glucose homeostasis at this age. In contrast, 12-week-old *NesCreIrs2KO* mice exhibited an increased β cell mass, evidence of a compensatory response to insulin resistance (Figure 3F, left). *POMCCreIrs2KO* did not display altered β cell mass compared with age-matched controls (data not shown).

To investigate the preservation of glucose homeostasis compared with *Irs2*-null mice, we examined β cell mass in 9-month-old *RIPCreIrs2KO* mice. *RIPCreIrs2KO* mice had a reduced islet area compared with control animals (Figure 3F, right), but the area had increased from that seen in 12-week-old *RIPCreIrs2KO* mice, which suggests partial recovery in β cell mass (Figure 3F, right).

Hypothalamic function in *RIPCreIrs2KO*, *NesCreIrs2KO*, and *POMCCreIrs2KO*

mice. *RIPCreIrs2KO* and *NesCreIrs2KO* mice displayed increased body weight compared with control mice starting around 4–5 weeks of age. By 12 weeks of age, they were 20% heavier than control animals (Figure 4A). *RIPCreIrs2KO* and *NesCreIrs2KO* mice were significantly longer than control mice (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI200524445DS1). MRI scanning performed at 16 weeks showed increased fat mass that was more significant in *NesCreIrs2KO* mice (Figure 4B). At 12 weeks, 24-hour food consumption was greater in both *RIPCreIrs2KO* and *NesCreIrs2KO* mice than in control animals (Figure 4C). In contrast, analysis of resting metabolic rate, core temperature, and activity revealed no differences between *RIPCreIrs2KO* or *NesCreIrs2KO* mice and control animals (Supplemental Table 1). Furthermore *POMCCreIrs2KO* mice did not display increased body weight (Figure 4A), were of the same length as controls (Supplemental Figure 1), and did not eat more than control mice (Figure 4C).




Figure 4

Hypothalamic function in *RIPCreIrs2KO*, *NesCreIrs2KO*, and *POMCCreIrs2KO* mice. **(A)** Body weight was measured in 12-week-old male mice of the indicated genotypes. **(B)** Total body fat was determined by MRI in 16-week-old male mice of the indicated genotypes. **(C)** Cumulative 24-hour food intake was measured in 12-week-old male mice of the indicated genotypes. **(D)** Fasting blood leptin levels of 12-week-old male mice of the indicated genotypes were measured after a 16-hour overnight fast. **(E–G)** Cumulative food intake, percent reduction in food intake compared with baseline, and reduction in bodyweight were measured over a 3-day period of treatment with leptin (5 mg/kg) or vehicle in 6–8-week-old male mice of the indicated genotypes. **(H)** Food intake and fasting leptin levels were determined in 5-week-old male mice of the indicated genotypes. Data in **A–H** represent the mean \pm SEM for 8–10 animals of each genotype. * $P < 0.05$, ** $P < 0.01$, and *** $P < 0.001$.

At 12 weeks of age when *RIPCreIrs2KO* and *NesCreIrs2KO* mice displayed marked obesity, leptin levels were significantly elevated in these mice but not in *POMCCreIrs2KO* mice (Figure 4D). We administered leptin (5 mg/kg) peripherally for 3 days to acclimatized 6-week-old mice. This treatment inhibited cumulative 3-day food intake in control animals by 20% compared with vehicle-treated animals (Figure 4, E and F). *RIPCreIrs2KO* and *NesCreIrs2KO* mice, despite being hyperphagic, also responded to leptin treatment with a 20% decrease in cumulative food intake (Figure 4, E and F). The reduction in food intake was accompanied in control, *RIPCreIrs2KO*, and *NesCreIrs2KO* mice by a significant reduction in body weight (Figure 4G). To further investigate the temporal development of the feeding phenotype, we measured leptin levels and food intake in 5-week-old male *RIPCreIrs2KO* mice. At this age, *RIPCreIrs2KO* mice were hyperphagic but did not display hyperleptinemia (Figure 4H). Findings for *NesCreIrs2KO* mice were similar (data not shown).

Characterization of β cell recovery in *RIPCreIrs2KO* mice. Our studies and others (13, 15, 19) raise the question of the mechanism for the relative recovery of the β cell mass in *RIPCreIrs2KO* mice with age. Analysis of 4-week-old *RIPCreIrs2KOZEG* mice demonstrated that a vast majority of insulin-positive cells coexpressed GFP, which suggests that recombination was occurring in most β cells (Figure 5, A and B). However, we detected small numbers of insulin-expressing cells that were GFP negative (Figure 5B), which indicates lack of recombination and that the *RIPCre* promoter was not active in all β cells. It would be predicted that *Irs2* would not be deleted in these cells and therefore they are involved in the preservation or recovery of β cell mass. Indeed, analysis of 9-month-old *RIPCreIrs2KOZEG* mice demonstrated that in many islets, a significant proportion of the insulin-positive β cells no longer expressed GFP (Figure 5, C and D). Comparison of the numbers of GFP-positive β cells in 9-month-old mice demonstrated that GFP expression loss occurred significantly more often in *RIPCreIrs2KOZEG* than control mice (percentage of GFP-negative β cells: *RIPCreIrs2KOZEG*, 50.9% \pm 1.2% vs. *RIPCreZEG*, 10.1% \pm 1.1%; $P < 0.001$; 2,062 β cells sampled in 54 islets from 4 *RIPCreIrs2KOZEG* mice and 2,987 β cells sampled in 45 islets from 3 *RIPCreZEG* mice).




Figure 5 Analysis of recombination and duct-marker expression in islets from *RIPCreIrs2KOZEG* mice. **(A–D)** Immunofluorescence staining for insulin (red) in islets from 4-week-old **(A and B)** and 9-month-old **(C and D)** *RIPCreIrs2KOZEG* mice stained for DNA (DAPI, blue). White arrows indicate β cells that do not express GFP and have not undergone recombination. Many cells in the 9-month-old islet do not express GFP. **(E–G)** Labeling of ducts with DBA in islets from 9-month-old *RIPCreIrs2KOZEG* mice stained blue for either DNA **(E and F)** or insulin **(G)**. No duct marker is expressed in GFP-negative β cells. Scale bars: 100 μ m.

To further characterize the mechanism of β cell recovery, we used a duct-specific lectin (*Dolichos biflorus* agglutinin [DBA]) to identify duct epithelial cells (20). GFP or insulin expression was not detected in DBA-positive duct structures in *RIPCreIrs2KOZEG* mice at 9 months of age (Figure 5, E–G). Likewise, in 9-month-old *RIPCreIrs2KOZEG* mice, in 296 islets sampled from 4 mice, no DBA-positive cells were found within islets (Figure 5, E–G). These findings suggest that duct cells that have differentiated to insulin-producing cells within ducts or duct cells that migrate to islet structures before converting to β cells do not make a significant contribution to the β cell repopulation. These findings do not exclude the possibility that ductal precursor cells that express neither duct markers nor insulin are involved in this process.

Characterization of *RIPCre* neurons and comparison with *POMC* neurons. Our studies demonstrate that *RIPCre* neurons play a role in energy homeostasis and growth and that deletion of *Irs2* in these cells generates a phenotype with similarities to that of melanocortin pathway mutants. However, our genetic evidence suggests that deletion of *Irs2* in *POMC* neurons does not account for the hypothalamic phenotype seen

in *RIPCreIrs2KO* or *NesCreIrs2KO* mice. RT-PCR analysis of expression of hypothalamic feeding peptides in *RIPCreIrs2KO* and *NesCreIrs2KO* mice demonstrated reduced POMC expression (POMC mRNA: 42% reduction in *NesCreIrs2KO* mice normalized to control mice, $P < 0.05$, $n = 5$; 48% reduction in *RIPCreIrs2KO* mice normalized to control mice, $P < 0.05$, $n = 8$) but normal neuropeptide Y (NPY) and agouti-related protein (AgRP) expression (data not shown), which suggests an effect on melanocortin circuits. No alteration in hypothalamic POMC, AgRP, and NPY expression was seen in *POMCCreIrs2KO* mice. Therefore, to characterize the relationship between RIPCre neurons and melanocortin pathways, we performed ISH/ICC analysis and electrophysiological studies of RIPCre and POMCCre neurons. POMC- and GFP-expressing neurons in the hypothalamus were clearly identified by ISH and ICC, respectively, in the same slices (Figure 6, A and B), and no GFP-positive neurons colocalized with POMC mRNA. POMC and RIPCre neurons, however, are closely associated with each other. Similarly, no coexpression of GFP was demonstrated in NPY neurons, but close apposition of these neuronal populations was observed (Figure 6, C and D). Combined ICC for α -melanocyte-stimulating hormone (α MSH) and GFP demonstrated no coexpression, but many GFP neurons were in close proximity to α MSH-positive fibers, which suggests that they may be targets for POMC neurons (Figure 6E).




Figure 6

Characterization of RIPCre neurons by ICC, ISH, and electrophysiological analysis. (A and B) Dual ISH for POMC and ICC for GFP was performed on hypothalamic sections from RIPCreZEG mice. Representative low- (A) and high-power (B) views are shown. (C and D) Dual ISH for NPY and ICC for GFP was performed on hypothalamic sections from RIPCreZEG mice. Representative low- (C) and high-power (D) views are shown. ARC, arcuate nucleus. (E) Fluorescence ICC for POMC was performed on hypothalamic sections from RIPCreZEG mice. Neurons expressing POMC are red and those expressing GFP are green. Arrows indicate noncolocalized neurons and GFP neurons that are abutted by POMC fibers. A representative confocal image is shown. Scale bars: 50 μ m (A and C) and 10 μ m (B, D, and E). (F–I) Current-clamp recordings were made from RIPCreZEG neurons in the absence and presence of the mixed melanocortin 3/4 receptor agonist MTII, as indicated above the traces. (F) Representative recording demonstrating MTII depolarization, resulting in a small increase in spike frequency (G). This depolarization is more clearly represented in neurons that have sub-spike thresholds, achieved by application of a constant hyperpolarizing current (H). MTII also depolarizes neurons in the presence of TTX (I), indicative of a direct action. The action potentials in panel H have been truncated to show clearly the depolarizing effect of MTII. Note that the MTII depolarization was irreversible over the time course of the recordings in cells represented in H and I.

Whole-cell current-clamp recordings were made from GFP-positive hypothalamic arcuate neurons from *RIPCreZEG* mice. Under control recording conditions, RIPCre neurons spontaneously fired action potentials and had a mean resting potential of -50 ± 1 mV and input resistance of $1,862 \pm 197$ M Ω ($n = 62$). Bath application of the α MSH analog melanotan II (MTII) (a nonselective melanocortin 3/4 receptor agonist) at 100 nM caused long-lasting depolarization in the majority of cells tested (from -53 ± 3 mV to -48 ± 2 mV; $P < 0.01$; $n = 9/13$), associated with increased spike firing (Figure 6, F and G).

To demonstrate the MTII excitatory effect more clearly, we applied a small hyperpolarizing current to individual neurons, such that action potential frequency was markedly reduced. Under these conditions, MTII (100 nM) caused depolarization and increased firing frequency (Figure 6H). Furthermore, the application of MTII (100 nM) to RIPCre neurons, following incubation of the slice with tetrodotoxin (TTX; 500 nM) to block spike firing and prevent synaptic transmission, caused significant depolarization ($n = 4$), which indicates a direct action (Figure 6I). To further characterize RIPCre neurons and differentiate them from POMC (and NPY) neurons, we determined the actions of insulin and leptin on the electrical properties of RIPCre and POMC neurons. Leptin has been demonstrated to depolarize POMC neurons (21), and our current results support this finding. Pressure ejection of leptin (50 nM) for 60 seconds directly above the recorded neuron caused an increase in spike frequency and a small depolarization (from -47 ± 2 mV to -44 ± 3 mV; $P < 0.04$) of a minority population of POMC neurons ($n = 5/13$) (Figure 7, A–C). In contrast, leptin (50 nM) did not affect action potential frequency or resting membrane potential (-46 ± 3 mV vs. -47 ± 3 mV; $n = 10$; Figure 7, D and E) in RIPCre neurons. Pressure ejection of insulin (10 nM) for 60 seconds produced a significant increase in action potential frequency, concomitant with cell depolarization (from -49 ± 4 to -40 ± 4 mV; $P < 0.01$) in the majority of recordings ($n = 6/9$) from RIPCre neurons (Figure 7, F–H). In contrast, pressure injection of insulin (10 nM) onto POMC neurons resulted in hyperpolarization (from -48 ± 1 mV to -55 ± 2 mV; $P < 0.001$) and reduced action potential frequency in most ($n = 9/11$) neurons (Figure 7, I and J). The effect of insulin, MTII, and leptin on neuronal activity was extremely slow to reverse and was, in many cases, irreversible over the time

course of the experiments. These experiments suggest that RIPCre neurons are a population distinct from either POMC or NPY neurons but lie within a melanocortin- and insulin-regulated neuronal mechanism.




Figure 7

Electrophysiological characteristics of RIPCre and POMC neurons in response to insulin and leptin.

(A) Representative recordings from individual arcuate neurons are shown for POMCCreZEG (A–C, I, and J) and RIPCreZEG (D–H). Leptin (50 nM) and insulin (10 nM) were pressure-ejected (2–5 psi) for 60 seconds (as denoted by arrows). (A) Leptin depolarizes the POMCCreZEG neuron, and this is associated with significant attenuation of spike amplitude. The recording from the neuron shown in B was hyperpolarized to subthreshold potentials by injection of constant current (2–5 pA) through the recording electrode. Application of leptin depolarized and increased the firing rate of the neuron. (C) Diary plot of spike frequency for the neuron shown in B. In contrast, leptin had no effect on membrane potential (D) and spike frequency (E) in RIPCreZEG neurons. Insulin caused depolarization of the RIPCreZEG neuron (F) and increased spike frequency (G), with spike attenuation. As shown in H, the neuron was hyperpolarized to subthreshold potentials as above, and application of insulin clearly depolarizes this neuron with a large increase in spike frequency. In contrast, insulin caused hyperpolarization of POMCCreZEG neurons (I), which was accompanied by a reduction in firing rate (J).

Discussion

Through global gene deletion, we and others have previously implicated *Irs2* in the regulation of β cell function and peripheral glucose metabolism and the central regulation of energy homeostasis (10, 11, 19, 22). These studies have suggested but not proved that *Irs2* mediates both β cell growth and leptin and insulin action in the CNS. To elucidate the contribution of *Irs2* to this complex phenotype in specific tissues, we generated mice with a conditional allele of *Irs2* to permit deletion in a number of cell types. We initially used RIPCre transgenic mice to generate *RIPCreIrs2KO* mice lacking *Irs2* in β cells and a population of hypothalamic neurons, and indeed it has recently been reported that *RIPCreIrs2KO* mice display phenotypes due to this mixed pattern of deletion (13, 14). These mice developed reduced β cell mass, obesity, somatic overgrowth, hyperinsulinemia, and hyperleptinemia but did not progress to an overt diabetic phenotype because of an unexplained recovery in β cell mass. However, because of the inability to dissociate β cell and hypothalamic phenotypes, a number of questions regarding the role of *Irs2* remain unanswered (15). To directly address such issues that we encountered with our own *RIPCreIrs2KO* mice, we also generated *NesCreIrs2KO* mice, lacking *Irs2* in all neurons but not the endocrine pancreas, and *POMCCreIrs2KO* mice, lacking *Irs2* in hypothalamic POMC neurons, which have been implicated in mediating leptin's effects on energy homeostasis (23).

Consistent with recent reports (13, 14), 12-week-old *RIPCreIrs2KO* mice had reduced β cell mass and displayed mildly elevated fasting blood glucose levels, impaired glucose tolerance, and hyperinsulinemia. They developed a marked hypothalamic phenotype resembling that of mice with defects in melanocortin action. In contrast, *NesCreIrs2KO* mice, which have normal β cell *Irs2* expression, had increased β cell mass in response to insulin resistance and displayed the obesity and overgrowth syndrome. These findings demonstrate that β cell mass reduction is due to *Irs2* deletion solely in β cells and not in the CNS. However, *NesCreIrs2KO* did develop elevated fasting blood glucose levels and hyperinsulinemia, which suggests that neuronal *Irs2* pathways are required for normal glucose homeostasis but that the increase in β cell mass seen in *NesCreIrs2KO* mice could compensate for insulin resistance.

In contrast to Lin et al. (13), we found that in 9-month-old *RIPCreIrs2KO* mice, there was a persistent reduction in β cell mass compared with that of control mice, although the mass was increased compared with that of 3-month-old *RIPCreIrs2KO* mice. At later ages, therefore, *RIPCreIrs2KO* mice had glucose intolerance but did not display marked fasting hyperglycemia and never developed the marked progressive diabetic phenotype of the global *Irs2*-null mouse. Anatomical studies of recombination using a GFP indicator mouse in either a wild-type or *Irs2^{fllox}* background revealed that as early as 4 weeks, small numbers of β cells did not harbor the recombination event. By 9 months of age, significant numbers of β cells in *RIPCreIrs2KO* mice not expressing GFP had repopulated the islets, but many GFP-positive cells undergoing recombination were still present, which explains the persistent reduction in β cell mass. Our studies demonstrate that the reduction in recombination occurs predominantly in *RIPCreIrs2KOZEG* as opposed to *RIPCreZEG* islets, which suggests that *Irs2* signaling itself is required for expression of the *RIPCre* transgene. Indeed, insulin gene expression appears to require an intact insulin signaling pathway in the β cell (2, 24, 25). With *Irs2* largely absent within β cells, under conditions of insulin resistance there may be potential selection for preexisting

β cells not expressing the *RIPCre* transgene and therefore not undergoing deletion of *Irs2* to expand and repopulate the islet. In 9-month-old mice, we did not detect GFP expression and Cre-mediated recombination in pancreatic ducts, and so potentially the GFP-negative β cells could have arisen from duct cells. However, we could not detect expression of a duct cell marker within islets of 9-month-old *RIPCreIrs2KO* mice nor could we find insulin expression in ducts. The absence of deletion in ducts also suggests that the β cell phenotype in *RIPCreIrs2KO* mice results from loss of *Irs2* in mature insulin-producing cells rather than any precursor or stem cell population. Taken together, these findings provide anatomical evidence that a small number of preexisting β cells that escape *Irs2* deletion at an early stage in *RIPCreIrs2KO* mice repopulate the islets. Our studies cannot categorically exclude the possibility that duct-derived precursors expressing neither insulin nor duct markers contribute to the repopulation process. However, recent lineage tracing studies (20) suggest that proliferation of mature β cells is the major mechanism for β cell expansion in adult mice. Our findings suggest that persistent *Irs2* expression in mature β cells is required for the compensatory response to insulin resistance.

The preservation of β cell mass in *NesCreIrs2KO* mice dissociates hypothalamic dysfunction from reduced β cell mass. It has been suggested that nestin expression is a characteristic of pancreatic islet stem cells (26, 27), but recently lineage tracing studies, utilizing the same *NesCre* mouse used in our studies, demonstrated that pancreatic exocrine, ductal, and endothelial cells but not islet endocrine cells express nestin (18, 28). The finding of increased islet mass in *NesCreIrs2KO* mice further supports the concept that nestin-positive cells do not contribute to the endocrine pancreas, as deletion of *Irs2* in these cells would have been anticipated to reduce β cell mass.

The hypothalamic phenotypes seen in *RIPCreIrs2KO* and *NesCreIrs2KO* mice suggested defects in melanocortin function, and in *RIPCreIrs2KO* and *NesCreIrs2KO* mice, we detected reduced hypothalamic POMC expression. Deletion of the leptin receptor in POMC neurons generates mice that have some phenotypic features in common with *RIPCreIrs2KO* mice, including obesity (23). It has been suggested that *RIPCre* neurons are POMC neurons and that *Irs2* signaling events are required for central leptin action (14, 29). Our results, however, do not confirm these findings and provide evidence to define the role and sites of *Irs2* pathways in the CNS. We demonstrate that deletion of *Irs2* in POMC neurons did not recapitulate the hypothalamic phenotype and that *RIPCre* neurons do not express POMC or NPY. Furthermore, *RIPCreIRS2KO* and *NesCreIRSKO* mice were sensitive to peripherally administered leptin at 6 weeks of age. Five-week-old *RIPCreIRS2KO* and *NesCreIRSKO* mice are hyperphagic but not hyperleptinemic, which suggests that elevated leptin levels seen at later ages result from greater adiposity due to increased energy intake rather than primary central leptin resistance. This is consistent with the observation that central leptin administration to *Irs2*-null mice causes reduction in fat mass (12). Young nonobese hyperphagic *melanocortin 4 receptor*-null mice, which resemble *RIPCreIRS2KO* and *NesCreIRSKO* mice, are sensitive to the anorexigenic effects of leptin but develop leptin resistance as they become obese (30). In preliminary observations, mice lacking *Irs2* in AgRP neurons, generated using an *AgRPCre* transgenic mouse (31), also do not develop a marked hypothalamic phenotype (H. Al-Qassab et al., unpublished observations). Therefore, these studies implicate *Irs2* signaling in neurons distinct from POMC and AgRP/NPY populations in the regulation of energy homeostasis and growth and suggest that *Irs2* is not an obligatory component of CNS leptin signaling pathways.

Electrophysiological analysis showed that *RIPCre* neurons depolarized in response to insulin and MTII, which suggests that they could be mediating the effects of insulin in the CNS in a melanocortin-sensitive neuronal pathway. Furthermore, we found no electrophysiological effect of leptin upon arcuate *RIPCre* neurons, which suggests that this is not a leptin-sensitive neuronal population and therefore may explain why *RIPCreIRS2KO* mice are not leptin resistant. In contrast, leptin depolarized and insulin hyperpolarized POMC neurons. These opposite effects upon neuronal activity perhaps explain the lack of phenotype in *POMCCreIrs2KO* mice and distinguish *RIPCre* neurons electrophysiologically from both POMC and NPY neurons (21, 32). It remains possible that the *RIPCre* neurons in other hypothalamic regions such as the VMH may be mediating the effects of leptin, and we have started to examine this possibility using additional mouse mutants. However, our observation of leptin sensitivity in the *NesCreIrs2KO* mice suggests that CNS *Irs2* is not required for leptin action.

Our studies have demonstrated that CNS *Irs2* pathways acting in a neuronal population distinct from POMC and NPY neurons regulate energy homeostasis and growth. Arcuate *RIPCre* neurons are targets for insulin and melanocortin but not leptin action, but it remains to be determined what neuropeptides and transmitters are expressed in this population. *Irs2* in β cells is required for the maintenance of β cell mass, but β cells that escape Cre-mediated recombination are able to repopulate islets with time. Our observations clarify the role of *Irs2* in β cell function and energy homeostasis and suggest that modulation of *Irs2* function may be of use in the treatment of diabetes and obesity.

Methods

Generation of floxed allele of *Irs2* and genotyping strategies for *Irs2lox* and *Cre* and *ZEG* transgenic mice.

The murine *Irs2* gene was cloned from a 129Sv mouse genomic PAC library. We cloned 2.8 kb of 5' homology from the *Irs2* locus upstream of a floxed neomycin cassette using appropriate linkers. The *Irs2* coding region was subcloned with linkers, introducing a loxP site 3' to the *Irs2* coding region. A 3-kb fragment of 3' region of the *Irs2* locus was cloned downstream of this loxP site using linkers to generate the final construct (Figure 1A). 129Sv/EvTac1 ES cells were transfected with Pac1-linearized targeting construct by electroporation. Cells were subjected to selection with G418 and ganciclovir; surviving clones were expanded and genomic DNA extracted and subjected to analysis by PCR and Southern blotting to detect homologous recombination (Figure 1, B–D). Targeted clones were subsequently transfected with Cre recombinase plasmid to remove the neomycin cassette and screened by Southern blotting and PCR (Figure 1, C and D). ES cells were injected into blastocysts derived from C57BL/6J mice, which were implanted into pseudopregnant CD-1 foster mothers. Chimeric male mice were bred with C57BL/6J mice and germ-line transmission confirmed by PCR and Southern blot analysis. *Irs2lox* mice were intercrossed with C57BL/6J *RIPCre* and C57BL/6J *NesCre* mice obtained from the Jackson Laboratory (33, 34) to generate compound heterozygous mice. Double-heterozygous mice were crossed with *Irs2lox* mice to obtain WT, *Irs2lox/lox*, *Cre*, and *CreIrs2lox/lox* mice. Mice lacking *Irs2* in *RIPCre*-expressing cells were designated *RIPCreIrs2KO* and in nestin *Cre*-expressing cells *NesCreIrs2KO*. *POMCCre* mice were generated using a BAC transgenic approach (35). *POMCCre* mice were intercrossed with *Irs2lox* mice and bred as described above to obtain *POMCCreIrs2KO* mice. *ZEG* mice, which carry a Cre-activated GFP transgene (16), or *Rosa26lacZ* indicator mice (17) were intercrossed with the *RIPCre* and *POMCCre* mice and *Irs2lox* mice to obtain mice that express GFP or lacZ in *RIPCre*- or *POMCCre*-expressing cells as well as mice that also lack *Irs2* and express the indicator gene. Mice were maintained on a 12-hour light/dark cycle with free access to water and standard mouse chow (4% fat, RM1; Special Diet Services) and housed in specific pathogen-free barrier facilities. Mice were handled and all in vivo studies performed with approval by the Home Office (London, United Kingdom). All knockout and transgenic mice were studied with appropriate littermate controls. Wild-type, *Cre* transgenic and *Irs2lox/lox* mice were phenotypically indistinguishable, and equal numbers of the mice of these genotypes were used as controls. Genotyping of the mice was performed by PCR amplification of tail DNA. For *Irs2lox* genotyping, we used primers that flank the 3' loxP site (Figure 1E): loxP forward, 5'-ACTTGAAGGAAGCCACAGTCG-3' and loxP reverse, 5'-AGTCCACTTTCCTGACAAGC-3'. Cre recombinase, *Rosa26lacZ*, and *ZEG* genotyping was performed as previously described (16, 17). For detection of Cre-mediated excision of *Irs2*, genomic DNA was isolated from pancreatic islets, hypothalamus, and other tissues by heating in 50 mM NaOH at 100°C for 10 minutes. Primers located 1.1 kb upstream of the 5' loxP site (5'-GGGAACCTGACAAGTGAATG-3') and 0.2 kb downstream of the 3' loxP site (loxP 5'-AGTCCACTTTCCTGACAAGC-3') amplified a 1.3-kb product if recombination had occurred.

Immunoprecipitation and Western blotting. Tissues were removed and homogenized in lysis buffer, solubilized for 30 minutes on ice, and clarified by centrifugation. Supernatants were immunoprecipitated for 2 hours with an anti-*Irs2* antibody as described (10). Immune complexes were collected with 100 µl of 50% slurry of protein A-sepharose, washed with lysis buffer, resolved on 7.5% SDS-PAGE, and transferred to nitrocellulose. The blots were probed with polyclonal antibody against *Irs2* and enhanced chemiluminescence (Amersham Biosciences) detection.

Metabolic studies. Body weights were determined using a Sartorius BP610 balance. Nose to anus length was measured either postmortem or in anesthetized mice, with the observer blinded to genotype. Blood samples were collected from mice via tail vein bleeds or from cardiac puncture performed on terminally anesthetized mice. Blood glucose was measured using a Glucometer Elite (Bayer Corp.). We determined plasma insulin levels using an ultrasensitive rat insulin ELISA (Crystalchem Inc.) using a mouse standard and leptin levels using a mouse leptin ELISA (Crystalchem Inc.). Glucose tolerance tests were performed on mice after a 16-hour overnight fast. Animals were injected intraperitoneally with D-glucose (1.5 g/kg) and blood glucose levels determined at the time points indicated in Figure 3, B and C.

Food intake and leptin and treatment studies. Mice were singly housed and allowed to acclimatize for a week prior to study. Food intake and body weight were measured for 3 consecutive days at the ages indicated in the Figure 4 legend. As necessary, we acclimatized mice by subjecting them to overnight fasts and sham injections prior to the study protocol. For peripheral leptin treatment, mice were treated with either 5 mg/kg recombinant mouse leptin (R&D Systems) or vehicle injected i.p. 1 hour before lights out for 3 consecutive days. Food and body weights were recorded before injection, during the treatment period, and for a 3-day wash-out period following the study.

ICC and ISH. Brains were harvested following transcardiac perfusion with RNase-free PBS and 4% paraformaldehyde, postfixed in 4% paraformaldehyde, and transferred to RNase-free 30% sucrose prior to freezing. Thirty-micrometer floating sections were cut using a sliding microtome. Twenty-micrometer cryostat sections were thaw-mounted on polylysine-coated microscope slides. Floating sections were washed in potassium PBS (KPBS), pH 7.4, blocked with 2% serum in KPBS/0.4% Triton X-100 (KPBS-T) for 1 hour at room temperature, and then incubated with primary antibodies in KPBS-T for 48 hours at 4°C. Slices were incubated with appropriate secondary antibodies for 1 hour in KPBS-T before being washed in KPBS. For chromogenic detection, slices were incubated for 60 minutes in avidin-DH/biotinylated HRP (ABC Elite; Vector Laboratories) in KPBS-T and washed in KPBS, then in 150 mM sodium acetate, and nickel-enhanced detection was performed with a 3,3'-diaminobenzidine substrate kit for peroxidase (Vector Laboratories). For some anti- α MSH staining experiments, mice were treated with intracerebroventricular colchicine (2 μ l of 20 mg/ml solution in 0.9% saline infused over 10 minutes into the lateral ventricle) 24 hours prior to perfusion fixation and biotinylated tyramide amplification and fluorescent detection with streptavidin-conjugated Alexa Fluor 594 (Invitrogen Corp.) were used. Slices were mounted on polylysine-coated microscope slides and coverslipped with buffered glycerol. Primary antibodies used were rabbit anti-Irs2 antibody (United Biomedical Inc.), sheep anti-NPY (Chemicon International), sheep anti- α MSH (Chemicon International), mouse monoclonal anti-GFP (Chemicon International), and mouse monoclonal anti-lacZ (Promega). For combined ISH and ICC, ISH was performed first under RNase-free conditions. In brief, sections on slides were fixed in formaldehyde solution for 20 minutes on ice, washed twice in PBS for 5 minutes, and acetylated at room temperature for 10 minutes in 0.1 M triethanolamine (pH 8.0) with acetic acid anhydride. After washing, sections were dehydrated and air dried for 30 minutes. Hybridization buffer containing 2 ng/ μ l digoxigenin-labeled (DIG-labeled) probe was applied and sections covered with glass coverslips and hybridized overnight at 60°C. Sections were placed in 4 \times SSC to remove coverslips, RNase A treated for 30 minutes at 37°C, and washed in 2 \times SSC at 6°C for 10 minutes, 1 \times SSC at 6°C for 10 minutes, 0.5 \times SSC at 60°C twice for 10 minutes, and 0.1 \times SSC at 60°C for 30 minutes. Sections were cooled to room temperature in 0.1 \times SSC, and we used alkaline phosphatase-conjugated anti-DIG antibody to detect bound DIG-labeled probe (Roche Diagnostics Ltd.) as described above. We generated ISH riboprobes using mouse sequences (POMC, GenBank accession number NM_008895; NPY, GenBank accession number NM_023456). Imaging was performed with an Olympus BX51 microscope with either a Hamamatsu 95 black-and-white camera or a Jenoptik ProgRes C14 color camera combined with SimplePCI capture and deconvolution software (version 5.2.1, Compix Inc.). Confocal microscopy was performed on a Bio-Rad MRC1000 microscope. Colocalization of either POMC or NPY with GFP was scored in 4 arcuate sections from each of 4 *RIPCreZEG* mice by 2 independent observers.

Pancreatic ICC and measurement of islet mass and number. Pancreata were removed, cleared of fat and lymph nodes, fixed in Bouins solution, embedded in paraffin, and cut into 5- μ m sections. For GFP detection, pancreata were harvested from paraformaldehyde-perfused mice as described above. For insulin staining, sections were incubated with blocking solution containing PBS buffer with 5% normal chicken serum and 2% BSA for 30 minutes, and mouse anti-insulin antibody (clone K36aC10; Sigma-Aldrich) was then applied for 2 hours at room temperature or overnight at 4°C. The sections were then incubated with chicken anti-mouse IgG-AlexaFluor 488 conjugate (Invitrogen Corp.) for 2 hours at room temperature. Transmitted light and fluorescent images were captured as described above. For quantification of β cell area, we analyzed 5 pancreata per genotype at each time point using 4 sections at least 150 μ m apart from each other. For each section, the total area occupied by insulin-positive cells was scored using SimplePCI software. Results are expressed as the percentage of the total pancreatic area. Pancreatic ducts were labeled with biotinylated DBA lectin (Vector Laboratories), detection performed with fluorescently labeled streptavidin 610 (Invitrogen Corp.), and DAPI used to identify nuclei.

Islet isolation. Mice were sacrificed, the common bile duct cannulated, and its duodenal end occluded by clamping. Two milliliters of collagenase V solution (1 mg/ml in HBSS) was injected into the duct to distend the pancreas. The pancreas was excised, incubated at 37°C for 15 minutes, and mechanically disrupted in 10 ml of HBSS. Cellular components were collected by centrifugation (220 *g* for 1 minute) and resuspended in 10 ml of HBSS. Islets were handpicked under a microscope and washed once in HBSS. Islets were centrifuged at 15,600 *g* for 5 minutes and stored at -20°C until DNA or protein extraction.

mRNA quantification by RT-PCR analysis. Hypothalami were removed from fasted mice, homogenized in Trizol reagent (Invitrogen Corp.), and 1 μ g RNA was reverse transcribed using Taqman reagents (Applied Biosystems). Quantitative PCR was carried out with first-strand cDNA with primers for hypothalamic feeding peptides (23), using hypoxanthine ribosyl transferase as an internal control on an ABI Prism 7900HT sequence detection system, with SYBR green reagents (Applied Biosystems Inc.), and data analyzed according to the $2^{-\Delta\Delta CT}$ method (36).

Electrophysiology. Male *RIPCreZEG* and *POMCCreZEG* mice (8–16 weeks old) were killed by cervical dislocation. Brains were rapidly transferred to a ice-cold slicing solution containing 2.5 mM KCl, 1.25 mM NaH₂PO₄, 28 mM NaHCO₃, 0.5 mM CaCl₂, 7 mM MgCl₂, 7 mM D-glucose, 1 mM ascorbate, 3 mM pyruvate, and 235 mM sucrose and equilibrated with 95% O₂/5% CO₂ to give a pH of 7.4, and 350- μ m coronal brain slices were prepared using a Vibratome Series 1000. Arcuate nucleus slices were kept at room temperature in a normal external solution containing 125 mM NaCl, 2.5 mM KCl, 1.25 mM NaH₂PO₄, 25 mM NaHCO₃, 2 mM CaCl₂, 1 mM MgCl₂, 10 mM D-glucose, 15 mM D-mannitol, 1 mM ascorbate, and 3 mM pyruvate equilibrated with 95% O₂/5% CO₂, pH 7.4. For whole-cell recordings, slices were continuously perfused with normal external solution (in the absence of ascorbate and pyruvate and with CaCl₂ and MgCl₂ concentrations adjusted to 0.5 and 2.5 mM, respectively) at a rate of 5–10 ml/min. Neurons were identified using epifluorescence and differential interference contrast optics using an upright Zeiss Axioskop 2 FS plus microscope. Borosilicate patch pipettes (5–8 M Ω) were filled with an internal solution containing 130 mM potassium gluconate, 10 mM KCl, 0.5 mM EGTA, 10 mM HEPES, 1 mM NaCl, 0.28 mM CaCl₂, 3 mM MgCl₂, 3 mM NaATP, 0.3 mM tris-GTP, 14 mM phosphocreatine (pH 7.2). Data were recorded and stored on digital audio tape, which enabled off-line analysis. We examined changes in input resistance by monitoring membrane potential responses to negative, rectangular current pulses (5–20 pA, 200 ms, 0.05 Hz) injected via the recording electrode. Application of drugs was made via the bath perfusion system or locally by pressure ejection from a broken pipette (approximately 5- μ m tip) positioned approximately 50 μ m above the recorded neuron at the concentrations indicated.

MRI and magnetic resonance spectroscopy. Mice were scanned using a 4.7T Varian system under isoflurane anesthesia. Whole-body images (between 50 and 60 slices; 2 mm thick) were obtained for each mouse using a spin-echo sequence (TR4500/TE20). Semiautomatic image segmentation software (sliceOmatic version 4.2; Tomovision) was used to separate and quantify tissue volumes (37). For adipose tissue, the volume was multiplied by a correction factor of 0.9 in order to account for hydration (38).

Statistical analysis. All statistics were performed using GraphPad Prism 4 software and paired and unpaired Student's *t* tests and 2-way ANOVA, with Bonferroni post-hoc tests performed as appropriate.

Supplemental data

[View Supplemental data](#)

Acknowledgments

We thank Jonathan Godwin for blastocyst injections, Corinne Lobe for providing *ZEG* mice, Marika Charalambous for advice and discussion, Steven Lingard for technical assistance, and Andrew Tinker and Matthew Glyn for assistance with confocal microscopy. We thank the Biological Imaging Centre (BIC), Imaging Sciences Department, Imperial College London, for assistance with the MRI studies. The work was supported by grants from the Wellcome Trust (to A. Choudhury, C. Selman, M.A. Smith, M. Simmgen, K. Hisadome, M.L.J. Ashford, and D.J. Withers); the Biotechnology and Biological Sciences Research Council (BBSRC) (to M. Claret); the Medical Research Council (MRC; to H. Al-Qassab, I. Diakonov, J.D. Bell, R.L. Batterham, and D.J. Withers); Diabetes UK (to A. Choudhury and D.C. Bedford); the NIH (DK-48506, to G.S. Barsh); the Stanford Bio-X Interdisciplinary Initiatives Program (to G.S. Barsh); and by an AstraZeneca BBSRC CASE award (to H. Heffron). Part of this work was conducted within the *BetaCellTherapy* consortium that is supported as an integrated project by the sixth European Union–framework program. R.L. Batterham is an MRC Clinician Scientist. D.J. Withers is an MRC Senior Clinical Fellow.

Footnotes

Agharul I. Choudhury, Helen Heffron, Mark A. Smith, and Hind Al-Qassab contributed equally to this work.

Nonstandard abbreviations used: AgRP, agouti-related protein; DBA, Dolichos biflorus agglutinin; DIG, digoxigenin; ICC, immunocytochemistry; Irs, insulin receptor substrate; Irs2lox mice, mice with a floxed allele of *Irs2*; ISH, in situ hybridization; α MSH, a melanocyte-stimulating hormone; MTII, melanotan II; NesCreIrs2KO mice, mice lacking *Irs2* in nestin Cre-expressing cells; NPY, neuropeptide Y; POMC, proopiomelanocortin; POMCCreIrs2KO mice, mice lacking *Irs2* in POMC-expressing cells; RIP, rat insulin 2 promoter; RIPCre mice, mice expressing Cre under the

control of the rat insulin 2 promoter; RIPCreIrs2KO mice, mice lacking Irs2 in β cells and a poorly characterized population of hypothalamic neurons; TTX, tetrodotoxin; VMH, ventromedial hypothalamus.

Conflict of interest: The authors have declared that no conflict of interest exists.

References

1. DeFronzo, RA. Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. *Diabetes Rev.* 1997. **5**:177-268.
2. Kulkarni, RN, et al. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. *Cell.* 1999. **96**:329-339.
View this article via: [PubMed](#) [CrossRef](#)
3. Woods, SC, Lotter, EC, McKay, LD, Porte (Jr), D. Chronic intracerebroventricular infusion of insulin reduces food intake and body weight of baboons. *Nature.* 1979. **282**:503-505.
View this article via: [PubMed](#) [CrossRef](#)
4. Bruning, JC, et al. Role of brain insulin receptor in control of body weight and reproduction. *Science.* 2000. **289**:2122-2125.
View this article via: [PubMed](#) [CrossRef](#)
5. Obici, S, Feng, Z, Karkanias, G, Baskin, DG, Rossetti, L. Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats. *Nat. Neurosci.* 2002. **5**:566-572.
View this article via: [PubMed](#) [CrossRef](#)
6. Air, EL, et al. Small molecule insulin mimetics reduce food intake and body weight and prevent development of obesity. *Nat. Med.* 2002. **8**:179-183.
View this article via: [PubMed](#) [CrossRef](#)
7. Withers, DJ. Insulin receptor substrate proteins and neuroendocrine function. *Biochem. Soc. Trans.* 2001. **29**:525-529.
View this article via: [PubMed](#) [CrossRef](#)
8. Tamemoto, H, et al. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. *Nature.* 1994. **372**:182-186.
View this article via: [PubMed](#) [CrossRef](#)
9. Araki, E, et al. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. *Nature.* 1994. **372**:186-190.
View this article via: [PubMed](#) [CrossRef](#)
10. Withers, DJ, et al. Disruption of IRS-2 causes type 2 diabetes in mice. *Nature.* 1998. **391**:900-904.
View this article via: [PubMed](#) [CrossRef](#)
11. Burks, DJ, et al. IRS-2 pathways integrate female reproduction and energy homeostasis. *Nature.* 2000. **407**:377-382.
View this article via: [PubMed](#) [CrossRef](#)
12. Suzuki, R, et al. Both insulin signaling defects in the liver and obesity contribute to insulin resistance and cause diabetes in Irs2(-/-) mice. *J. Biol. Chem.* 2004. **279**:25039-25049.
View this article via: [PubMed](#) [CrossRef](#)
13. Lin, X, et al. Dysregulation of insulin receptor substrate 2 in β cells and brain causes obesity and diabetes. *J. Clin. Invest.* 2004. **114**:908-916. doi:10.1172/JCI200422217..
View this article via: [JCI.org](#) [PubMed](#)
14. Kubota, N, et al. Insulin receptor substrate 2 plays a crucial role in β cells and the hypothalamus. *J. Clin. Invest.* 2004. **114**:917-927. doi:10.1172/JCI200421484..
View this article via: [JCI.org](#) [PubMed](#)
15. Brady, MJ. IRS2 takes center stage in the development of type 2 diabetes. *J. Clin. Invest.* 2004. **114**:886-888. doi:10.1172/JCI200423108..
View this article via: [JCI.org](#) [PubMed](#)
16. Novak, A, Guo, C, Yang, W, Nagy, A, Lobe, CG. Z/EG, a double reporter mouse line that expresses enhanced green fluorescent protein upon Cre-mediated excision. *Genesis.* 2000. **28**:147-155.
View this article via: [PubMed](#) [CrossRef](#)
17. Soriano, P. Generalized lacZ expression with the ROSA26 Cre reporter strain. *Nat. Genet.* 1999. **21**:70-71.
View this article via: [PubMed](#) [CrossRef](#)
18. Delacour, A, Nepote, V, Trumpp, A, Herrera, PL. Nestin expression in pancreatic exocrine cell lineages. *Mech. Dev.* 2004. **121**:3-14.
View this article via: [PubMed](#) [CrossRef](#)

19. Kubota, N, et al. Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia. *Diabetes*. 2000. **49**:1880-1889.
View this article via: [PubMed](#) [CrossRef](#)
20. Dor, Y, Brown, J, Martinez, OI, Melton, DA. Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. *Nature*. 2004. **429**:41-46.
View this article via: [PubMed](#) [CrossRef](#)
21. Cowley, MA, et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. *Nature*.2001. **411**:480-484.
View this article via: [PubMed](#) [CrossRef](#)
22. Withers, DJ, et al. Irs-2 coordinates Igf-1 receptor-mediated beta-cell development and peripheral insulin signalling. *Nat. Genet*. 1999. **23**:32-40.
View this article via: [PubMed](#)
23. Balthasar, N, et al. Leptin receptor signaling in POMC neurons is required for normal body weight homeostasis. *Neuron*.2004. **42**:983-991.
View this article via: [PubMed](#) [CrossRef](#)
24. Leibiger, IB, Leibiger, B, Moede, T, Berggren, PO. Exocytosis of insulin promotes insulin gene transcription via the insulin receptor/PI-3 kinase/p70 s6 kinase and CaM kinase pathways. *Mol. Cell*. 1998. **1**:933-938.
View this article via: [PubMed](#) [CrossRef](#)
25. Kulkarni, RN, et al. Altered function of insulin receptor substrate-1-deficient mouse islets and cultured beta-cell lines. *J. Clin. Invest*. 1999. **104**:R69-R75.
View this article via: [JCI.org](#) [PubMed](#) [CrossRef](#)
26. Zulewski, H, et al. Multipotential nestin-positive stem cells isolated from adult pancreatic islets differentiate ex vivo into pancreatic endocrine, exocrine, and hepatic phenotypes. *Diabetes*. 2001. **50**:521-533.
View this article via: [PubMed](#) [CrossRef](#)
27. Lumelsky, N, et al. Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets. *Science*.2001. **292**:1389-1394.
View this article via: [PubMed](#) [CrossRef](#)
28. Treutelaar, MK, et al. Nestin-lineage cells contribute to the microvasculature but not endocrine cells of the islet. *Diabetes*.2003. **52**:2503-2512.
View this article via: [PubMed](#) [CrossRef](#)
29. Tobe, K, et al. Increased expression of the sterol regulatory element-binding protein-1 gene in insulin receptor substrate-2(-/-) mouse liver. *J. Biol. Chem*. 2001. **276**:38337-38340.
View this article via: [PubMed](#) [CrossRef](#)
30. Marsh, DJ, et al. Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides. *Nat. Genet*.1999. **21**:119-122.
View this article via: [PubMed](#) [CrossRef](#)
31. Kaelin, CB, Xu, AW, Lu, XY, Barsh, GS. Transcriptional regulation of agouti-related protein (Agrp) in transgenic mice.*Endocrinology*. 2004. **145**:5798-5806.
View this article via: [PubMed](#) [CrossRef](#)
32. Roseberry, AG, Liu, H, Jackson, AC, Cai, X, Friedman, JM. Neuropeptide Y-mediated inhibition of proopiomelanocortin neurons in the arcuate nucleus shows enhanced desensitization in ob/ob mice. *Neuron*. 2004. **41**:711-722.
View this article via: [PubMed](#) [CrossRef](#)
33. Postic, C, et al. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. *J. Biol. Chem*. 1999. **274**:305-315.
View this article via: [PubMed](#) [CrossRef](#)
34. Tronche, F, et al. Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. *Nat. Genet*. 1999. **23**:99-103.
View this article via: [PubMed](#) [CrossRef](#)
35. Xu, AW, et al. PI3K integrates the action of insulin and leptin on hypothalamic neurons. *J. Clin. Invest*. 2005. **115**:951-958. doi:10.1172/JCI200524301..
View this article via: [JCI.org](#) [PubMed](#)
36. Livak, KJ, Schmittgen, TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods*. 2001. **25**:402-408.
View this article via: [PubMed](#) [CrossRef](#)
37. Ross, R, Leger, L, Guardo, R, De Guise, J, Pike, BG. Adipose tissue volume measured by magnetic resonance imaging and computerized tomography in rats. *J. Appl. Physiol*. 1991. **70**:2164-2172.

38. Tang, H, Vasselli, JR, Wu, EX, Boozer, CN, Gallagher, D. High-resolution magnetic resonance imaging tracks changes in organ and tissue mass in obese and aging rats. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 2002. **282**:R890-R899.